 |
(S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate |
|---|---|
| Trade Name | Xermelo |
| Orphan Indication | Carcinoid syndrome |
| EU Market Approval | EU |
| EU Designation Date | 2009-10-08 00:00:00 |
| Sponsor | Ipsen Pharma |
